AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01066377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic and probiotic mix
Description: The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10\^8 - 10\^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested).
Study NCT02232867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm and Leg Cycling Exercise Program
Description: Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
Study NCT03258242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keluo Xin capsule
Description: four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
Study NCT03258242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
Study NCT02620280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
Study NCT02620280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
Study NCT02620280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane
Description: Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
Study NCT02620280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
Study NCT02620280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
Study NCT02620280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
Study NCT02620280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
Study NCT02620280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthra
Description: AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
Study NCT02620280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthra
Description: AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
Study NCT00734565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b
Description: 1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
Study NCT02716740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week
Description: After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
Study NCT06491758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abvn
Description: A modality of therapy currently being utilized to treat focal or partial seizures that do not respond to seizure medications is called as VNS Therapy (Vagus Nerve Stimulation). This has been approved by FDA as an effective treatment for seizure disorders. Our aim is to study the HRV in patients undergoing this therapy as part of their regular mode of treatment. The specific aim is to measure the HRV in patients undergoing vagus nerve stimulation therapy.~During VNS treatment the stimulator is surgically implanted in the upper chest and stimulation electrodes are implanted in the left cervical vagus nerve.
Study NCT03774719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand-carried ultrasound
Description: Hand-carried ultrasound of both kidneys to detect the presence or absence of hydronephrosis. Device used will be the lumify portable ultrasound equipped with the C5-2 curved array transducer (Philips, USA).
Study NCT03445949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: short postimplantation dual antiplatelet therapy
Description: continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device
Study NCT03445949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: extended postimplantation dual antiplatelet therapy
Description: stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device
Study NCT03445949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: long-term treatment with a single antiplatelet agent
Description: continuing long-term treatment with single antiplatelet agent
Study NCT03445949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6 months treatment with a single antiplatelet agent
Description: continuing single antiplatelet agent up until 6 months
Study NCT02897661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WMT
Description: Washed microbiota transplantation (WMT) through mid-gut
Study NCT02897661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EEN
Description: Exclusive enteral nutrition (EEN) through feeding tube
Study NCT02140593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).
Study NCT02140593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
Study NCT04332458 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A focus group interview
Description: this is a qualitative study using focus group interviewing.
Study NCT03499535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Radon & Smoking Synergistic
Description: Participants viewed health information detailing the risks of developing lung cancer from exposure to radon gas, smoking, and their synergistic effects. This intervention represents the type of information most commonly presented in radon risk communications.
Study NCT03499535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radon Only
Description: Participants viewed health information detailing the risks of developing lung cancer from radon exposure. No information about the risks for developing lung cancer associated with smoking or its synergistic effect with radon exposure are included.
Study NCT03499535 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Radon and Smoking Isolated
Description: Participants viewed health information detailing the risks of developing lung cancer from radon exposure and smoking. No information describing the synergistic effects of smoking and radon exposure on lung cancer risk are included.
Study NCT03499535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPA
Description: Health information modeled after the Environmental Protection Agency's (EPA) pamphlet on radon risk.
Study NCT03499535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EPA
Description: Health information modeled after the Environmental Protection Agency's (EPA) pamphlet on radon risk.
Study NCT03499535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Idaho
Description: Health information modeled after the Idaho Department of Health and Human Welfare's pamphlet on radon risk.
Study NCT03499535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Idaho
Description: Health information modeled after the Idaho Department of Health and Human Welfare's pamphlet on radon risk.
Study NCT03508908 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV-1 RNA testing
Description: During the intervention period, a blood sample will be obtained and tested for AHI using point-of-care Xpert® HIV Qual assay (Cepheid, Sunnyvale, California, USA). Individuals who test positive will undergo rapid tests to differentiate acute from prevalent HIV infection. Newly diagnosed individuals will be offered immediate ART and assisted partner notification with the HIV-1 RNA testing intervention delivered to partners following the same approach.
Study NCT02460237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disease Screening
Description: Complete HPV self-test
Study NCT02460237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Disease Screening
Description: Complete HPV self-test
Study NCT02460237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
Study NCT02460237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive standard instructions and information sheet
Study NCT02460237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02460237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02460237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02460237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT00194649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca)
Description: 100 mg Miglustat BID (twice daily) for six weeks
Study NCT02467634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HuCNS-SC sub-retinal transplantation
Description: HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
Study NCT03456310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transperineal ultrasound
Description: trans-perineal US: B mode capable 2D ultrasound system with cine loop function, a 3.5-6.0 MHz curved array transducer. A mid-sagittal and axial views is obtained by placing a transducer on the perineum (Parting of the labia can improve image quality).~Dynamic MRI:~Magnetic resonance (MR) imaging of the pelvic floor is a two-step process that includes:~analysis of anatomic damage on axial fast spin-echo (FSE) T2-weighted images. then sagittal and coronal (FSE) T2-weighted are obtained.~functional evaluation using sagittal dynamic single-shot T2-weighted sequences during straining and defecation.
Study NCT03391245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique
Description: Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique using CALBIOTECH (A life science company) kit, Catalog No.: VD220B
Study NCT02207426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Study NCT00501787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT04427982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dance
Description: Participants will attend a 2-month weekly light-to-moderate intensity dance workshop.
Study NCT04427982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetes education
Description: The dance classes will be followed by a brief diabetes education and discussion session.
Study NCT02551549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101 IV
Description: antifungal
Study NCT02551549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT02182388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02182388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA powder for solution
Study NCT02182388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA tablet
Study NCT00166413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: 40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
Study NCT01274689 — intervention group
Intervention type: OTHER
Intervention: individually tailored lead weight
Description: patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
Study NCT04312646 — intervention group
Intervention type: DEVICE
Intervention: Elastography .
Description: Performance of US, elastography
Study NCT03114852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood collection
Description: They will have blood tested to renal genetic diseases
Study NCT01962363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Description: EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
Study NCT00881868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate spray 0.05%
Description: Apply enough product to cover affected areas topically twice daily at least 8 hours apart
Study NCT00881868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle spray
Description: Apply enough product to cover affected areas topically twice daily at least 8 hours apart
Study NCT02537015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
Study NCT04159298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Top Spin 360
Description: The TopSpin360 is a dynamic multi-planar neuromuscular training device that has been shown to improve static and dynamic multi-planar neck strength in a healthy athletic population
Study NCT01601652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: 1 g/kg/d iv infusion over 24h
Study NCT00658164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron depletion treatment
Description: Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores
Study NCT02103673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks
Study NCT02103673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention drug: placebo by mouth. Duration: 6 weeks
Study NCT02832362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbomer 980
Description: Test product containing 0.5% carbomer 980 gel
Study NCT02832362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reference product containing vehicle without 0.5% carbomer 980 gel
Study NCT03198624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0018318
Description: Part A single dose Part B five doses
Study NCT03198624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Part B only
Study NCT04917341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital
Description: The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.
Study NCT01657461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
Description: Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
Study NCT01657461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solitaire revascularization device
Description: Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
Study NCT00234754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT Surgery TOT Surgery
Description: TVT surgery and TOT surgery
Study NCT00234754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT Surgery TOT Surgery
Description: TVT surgery and TOT surgery
Study NCT04058132 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil Citrate 50Mg Tab
Description: sildenafil citrate (Viagra®, Pfizer. Inc., NY, NY). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo\[4,3-d\]pyrimidin-5-yl)-4- ethoxyphenyl\]sulfonyl\]-4-methylpiperazine citrate. Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. For this study, we will use 50 mg tablets for the single dose studies.
Study NCT04058132 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: functional Near-infrared Spectroscopy (fNIRS)
Description: Functional Near-Infrared Spectroscopy (fNIRS): Functional near-infrared spectroscopy (fNIRS) a noninvasive technique that can measure cerebrovascular reactivity (CVR) will be used to measure regional cerebral blood flow and cerebrovascular reactivity in the brain. The device (fNRIS100, fNIR Device LLC), uses laser emission diodes (730nm and 850nm)which in a headband that is worn on the front of the scalp and forehead. Surrounding detectors a few centimeters away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes. fNIRS will be performed twice at each study visit, once before and once about 45 minutes after single dose administration of sildenafil 50 mg.
Study NCT04058132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carbon Dioxide (CO2) 5%
Description: Carbon Dioxide (CO2) 5% mixed with room air. Both the fNIRS procedure and one Magnetic Resonance Imaging (MRI) session at visits that include imaging will be done with a hypercapnia challenge for comparison.~CO2 (hypercapnia) challenge is similar to holding one's breath. Participant will wear a nose clip and a mouth breathing apparatus while in the MRI scanner or sitting in a chair during the fNIRS procedure.~During the 7-minute hypercapnia procedure, participants will breathe room air and then switch to room air mixed with 5% CO2, from one to the other for one minute each.
Study NCT04058132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological Assessments
Description: TBI Neuropsychological Assessments: Study participants will be administered a set of Neuropsychological Tests designed by the NINDS Common Data Elements (CDEs) initiative for TBI, in order to provide a comprehensive and broad assessment of deficits commonly found after TBI. We anticipate that the neuropsychological battery will require approximately 1 hour to complete. The measures (pencil and paper exercises, questionnaires, and interview by the examiner) to be administered are: Glasgow Outcome Scale-Extended (GOS-E). Learning trials portion of the California Verbal Learning Test (CVLT-II): The Trail Making Tests A and B (TMT): Subsets of the Wechsler Adult Intelligence Scale (WAIS-IV) (Digit Symbol and Symbol Search): Behavioral Symptoms Inventory-18: Satisfaction with Life Scale (SWLS): Word Reading subtest of Wide Range Achievement Test (WRAT)-4: Rivermead Post-Concussion Symptom Questionnaire.
Study NCT04058132 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gadolinium contrast infusion
Description: Gadolinium contrast infusion: Brain MRI with gadolinium contrast: Dynamic contrast-enhanced (DCE) MRI with intravenous gadolinium-based contrast agents (GBCAs) to measure their transfer rate between intravascular and extravascular compartments as a marker of blood-brain barrier (BBB) permeability. For the DCE sequence, the participant is injected with the contrast agent through a heplock/iv in the scanner and the sequence takes about 15 min. Half-life of gadolinium is about 1 ½ hours and 90-98% clearance from the body in 24 hours in people with normal kidney function.
Study NCT04058132 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection for research purposes
Description: Serum and plasma (5 ml each) will be collected at at each study visit 10 m or 2 tsp. per visit or up to 40 ml or 8 tsp. over the 180 day course of the study). Samples will be collected by study personnel.